Bristol-Myers Squibb’s second-quarter financials have revealed continuing strong sales of the bloodthinner Plavix and its virolology franchise.

Net income from continuing operations came in at $927 million, up 5.3%, while group sales edged up 2.2% to $4.77 billion. Plavix (clopidogrel) was up 6% to $1.63 billion, though sales of the antipsychotic Abilify (aripiprazole) slipped 2% to $663 million.

As for the firm's HIV drugs, sales of the Sustiva (efavirenz) franchise rose 6% to $331 million, and Reyataz (atazanavir) was up 8% to $357 million. Revenues from Baraclude (entecavir) for hepatitis B climbed 25% to $223 million.

Moving on to B-MS’ newer drugs, Sprycel (dasatanib) for leukaemia rose 23% to $132 million, while Orencia (abatacept) for rheumatoid arthritis increased 20% to $178 million. The cancer agent Erbitux (cetuximab) dipped 1% to $172 million and Onglyza (saxagliptin), a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes partnered with AstraZeneca, brought in just $28 million.

B-MS is maintaining its full-year profit forecast (excluding items) of $2.10-$2.20 per share and said it continues to expect earnings of a minimum of $1.95 per share in 2013, the year after Plavix, which is partnered with Sanofi-Aventis, loses patent protection in the USA.